Press Releases and Events

PRESS RELEASES

Press Release | February 10, 2025

Crinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 10, 2025

Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 10, 2025

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | January 6, 2025

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

READ MORE
Press Release | December 16, 2024

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

READ MORE
Press Release | December 10, 2024

Crinetics Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | December 9, 2024

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

READ MORE
Press Release | November 15, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

READ MORE
Press Release | November 12, 2024

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

READ MORE
Press Release | November 12, 2024

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

READ MORE
6 / 25